Opportunity ID: 58910

General Information

Document Type: Grants Notice
Funding Opportunity Number: DARPA-BAA-11-23
Funding Opportunity Title: Controlling Cellular Machinery – Diagnostics and Therapeutics
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Procurement Contract
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards:
Assistance Listings: 12.910 — Research and Technology Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Nov 29, 2010
Last Updated Date:
Original Closing Date for Applications: Mar 03, 2011
Current Closing Date for Applications: Mar 03, 2011
Archive Date: May 03, 2011
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: DARPA – Defense Sciences Office
Description: DARPA is soliciting research proposals for the development of synthetic regulatory genetic elements that can be used in mammalian cells. The proposed research should comprise approaches that enable fundamental advances to the development and broad application of synthetic regulatory elements for in vivo biomedical applications to detect, treat, or prevent disease. Technical challenges that need to be addressed include, but are not limited to, discovery, characterization, evolution or design, and demonstration of orthogonal and modular genetic regulatory elements; construct stability and function in the cell; and synthesis, amplification, and delivery of novel circuits in mammalian cells. The designed modules must limit specific interactions with the cellular metabolism or milieu to the desired performance characteristics and demonstrate maintenance of independent function without interference long enough to achieve the intended clinical effect. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice. Proposers that intend to pursue nucleic acid vaccines as an application are referred to the companion announcement, Controlling Cellular Machinery – Vaccines, DARPA-BAA-11-22.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Dr. Daniel Wattendorf
Email:DARPA-BAA-11-23@darpa.mil

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: Dr. Daniel Wattendorf
Email: DARPA-BAA-11-23@darpa.mil
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.910 PKG00022669 Nov 29, 2010 Mar 03, 2011 View

Package 1

Mandatory forms

58910 RR_SF424-1.1.pdf

Optional forms

58910 RR_FedNonFedBudget-1.1.pdf

58910 RR_FedNonFed_SubawardBudget-1.2.pdf

58910 RR_OtherProjectInfo-1.1.pdf

58910 RR_Budget-1.1.pdf

58910 RR_KeyPersonExpanded-1.1.pdf

58910 RR_PerformanceSite-1.1.pdf

58910 RR_SubawardBudget-1.2.pdf

2025-07-12T10:08:49-05:00

Share This Post, Choose Your Platform!

About the Author: